HEALTH & LIFE SCIENCES NEWS

This Week in 340B: September 20 – 26, 2023

By Emily Jane Cook, Ming Chuang and Kelsey Reinhardt on Sep 27, 2023
Posted In 340B

This weekly series provides brief summaries to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary of relevant updates from the prior week in this industry-shaping body of litigation.

Issues at Stake: 340B Covered Entity, Contract Pharmacy

The prime vendor program appellee in a Ninth Circuit case requested an extension to file its appellee brief.
In a case involving anti-trust and tort claims, the court denied the plaintiff’s Motion for a Temporary Restraining Order and Preliminary Injunction.
In a case involving the definition of “patient,” a national 340B advocacy organization filed an Amicus Brief.
A drug manufacturer filed a complaint to invalidate a state law governing contract pharmacy arrangements.

Get more details on these 340B cases with the 340B Litigation Tracker, a subscription product from McDermott+Consulting.

VBC Symposium 2023 | Washington Update

By McDermott Will & Emery on Sep 26, 2023
Posted In Uncategorized

During this session, Mara McDermott, former Vice President, McDermott+Consulting, moderated a panel that discussed the current political and policymaking environment on Capitol Hill and what to watch for in 2023.

Session panelists included:

Dr. Lauren Lyles-Stolz, Senior Director, Reimbursement, Innovation and Advocacy, National Association of Chain Drug Stores (NACDS)
Aisha Pittman, Senior Vice President, Government Affairs, National Association of ACOs (NAACOS)
Soumi Saha, Senior Vice President of Government Affairs, Premier Inc.
Moderator: Mara McDermott, former Vice President, McDermott+Consulting

Top takeaways included:

Legislative and regulatory stakeholders have created a number of opportunities to engage in value-based care, including through the creation of the Center for Medicare and Medicaid Innovation (CMMI) and the Medicare Shared Savings Progam (MSSP). However, many of these initiatives have been—and continue to be—influenced by political and agency decision making. Therefore, educating members of Congress on why value is important remains a top priority.
Stakeholders are advocating for greater predictability and alignment across value-based initiatives. There are many competing interests in the system today, with Centers for Medicare & Medicaid Services (CMS) initiatives trending in different directions (e.g., Medicare Advantage versus MSSP). There are questions regarding how pharmacy services can better integrate into value-based care, how to engage specialists, how to sustain Medicare Advantage and more. Creating a pathway for all of these initiatives and stakeholders to coexist will be challenging, but could lead to greater value.
Better data is needed across programs. Faster, higher-quality data would allow CMS to more quickly cost-correct during the [...]

Continue Reading

This Week in 340B: September 12 – 19, 2023

By Emily Jane Cook, Ming Chuang and Kelsey Reinhardt on Sep 20, 2023
Posted In 340B

This weekly series provides brief summaries to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary of relevant updates from the prior week in this industry-shaping body of litigation.

Issues at Stake: 340B Covered Entity

A medical group filed an antitrust case in Pennsylvania federal court against a 340B covered entity.
In a case involving the definition of “patient”, the covered entity filed a reply brief.
The covered entity appellant in a Ninth Circuit case filed its opening brief against the prime vendor program appellee.

Get more details on these 340B cases with the 340B Litigation Tracker, a subscription product from McDermott+Consulting.

Top Takeaways | Specialty Spotlight: Gastroenterology

By McDermott Will & Emery on Sep 19, 2023
Posted In PPM/ASC

In this moderated session featuring perspectives from top gastroenterology (GI) executives, panelists explored the thriving state of marketing and dealmaking in this field.

Session panelists included:

Robbie Allen, Chief Executive Officer, One GI
Matt Devine, Chief Executive Officer, Allied Digestive Health
Michael Kroin, Chief Executive Officer and managing partner, Physician Growth Partners
Samuel Vaill, Chief Development Officer, United Digestive
Moderator: Amanda Jester, Partner, McDermott Will & Emery

Top takeaways included:

Gastroenterology continues to be an attractive specialty for investment. This is due to a number of factors, including gastroenterology’s diverse revenue streams that can provide income repair for physicians and generate alignment among stakeholders. The increased push for outpatient surgical care to lower costs of care and the decreasing age of patients seeking colonoscopies and other gastroenterology procedures provide investors with significant runways to drive growth.
As labor costs increase and challenges in the healthcare industry continue, physician practice management organizations provide gastroenterology groups with economies of scale, the ability to develop ancillaries and strong recruiting programs, as well as leverage against disruption by payors, hospital systems and competitors. Other advantages include access to expansive clinical data for research and development and improved point-of-care support.
Culture is an oft-overlooked factor in gastroenterology transactions. Because transactions are intended to foster long-term arrangements, ensuring cultural alignment is key for the future success of a platform. Physicians should also consider the ways in which the platform focuses on the physician and the support of their practice as well as the [...]

Continue Reading

An International Guide to Regulatory and Transactional Issues

By McDermott Will & Emery on Sep 14, 2023
Posted In Health M&A, Health Private Equity, Life Sciences Private Equity

In today’s rapidly evolving global healthcare landscape, market participants encounter a wealth of potential alongside a diverse range of challenges. We understand the importance of negotiating complex and ever-shifting regulations efficiently when structuring cross-border investments and transactions.

In our Guide, you’ll discover invaluable insights to help navigate the dynamic world of healthcare, unlocking opportunities and understanding the developing regulatory landscape.

Download the guide here!